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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.com(PE) of the study was target lesion failure (TLF) at 9 months. Out of 724 patients, 262
were enrolled in 15 centers in Japan.
Results: There were signiﬁcant differences in almost all baseline patient character-
istics: age (69 vs. 63 years), diabetes mellitus (41% vs. 31%), insulin dependent
diabetes mellitus (1% vs. 24%); acute coronary syndrome (5% vs. 35%), multivessel
disease (30% vs. 46%), in Japan and out of Japan respectively. There were no sig-
niﬁcant differences in lesion characteristics except that more bifurcations (23% vs.
11%; p< 0.01) and longer lesions were treated in Japan (16.7 vs. 15.6 mm: p¼0.02)
with 47% vs. 37% of treated lesions being longer than 20 mm. Radial access was more
frequently used in Japan (86% vs. 70%; p< 0.01). Pre-dilatation was done in 96% of
the lesions in Japan and 73% outside Japan (p< 0.01), while mean number of post
dilatations was 3.83.4 vs. 1.30.6 (p< 0.01) in Japan and outside Japan, res-
pectively. PE up to 4-month was not signiﬁcantly different between the groups (3.4
vs 3.9%).
Conclusions: Despite the signiﬁcant differences observed in several baseline patient
and procedure characteristics, short term results are very similar. One year data,
including results per study stent arm will be presented.
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Background: Clinical outcomes of percutaneous coronary intervention(PCI) for high
age patients has not well investigated in real-world setting.The aim of this study is to
examine clinical outcomes after PCI for high age patients.
Methods: This study was performed as a retrospective registry. Between February
2010 to June 2012, 1646 patients underwent PCI with NoboriTM biolimus-eluting
stent (BES) or everolimus eluting stent(EES). A total of 679 patients were over 75
years old. The main endpoints were major adverse cardiac or cerebrovascular even-
ts(MACE; deﬁned as cardiovascular death, stroke, myocardial infarction), target lesion
revascularization(TLR), target vessel revascularization(TVR), stent thrombosis(ST)
and freedom from any hemorrhagic complication. Mean follow-up was 1.70.7 years.
Results: Baseline characteristics were not signiﬁcantly different between the 2 groups.
At 2-year, the cumulative rate of MACE, TLR, TVR and ST were no signiﬁcant
different between the two groups. The cumulative rate of freedom from any hemor-
rhagic complication was lower in over 75 years old group (91.6% vs 96.1%,
P¼0.0002). After correcting all end points with baseline variables, use of dual anti-
platelet therapy for more than 2 years and use of clopidogrel were independent pre-
dictors for any hemorrhagic complication.Conclusions: We might suggest that use of dual antiplatelet therapy with clopidogrel
for more than 2 years is a risk factor of any hemorrhagic complication for high age
patients.
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Background: Coronary Artery Bypass Graft surgery (CABG) involving Internal
Mammary Artery (IMA) graft is considered superior to stenting for revascularization
of Left Anterior Descending (LAD) artery. Current generation Drug Eluting StentsB32 JACC Vol 64/11/Suppl B j Septemb(DES) are associated with extremely low target vessel revascularization (TVR) rates.
We sought to compare the outcomes of DES versus CABG for treatment of isolated
stenosis of proximal LAD artery.
Methods: PubMed, Cochrane and Web of Science databases were searched for
relevant articles in English language through April 30th 2014 comparing the outcomes
of DES versus CABG for revascularization of isolated proximal LAD stenosis. Out-
comes assessed were all-cause mortality, cardiovascular mortality, myocardial
infarction (MI), peri-procedure stroke and TVR. Study quality, publication bias and
heterogeneity were assessed. Analysis was done using DerSimonian and Laird random
effect model.
Results: From 339 publications, we identiﬁed 4 studies (2 randomized & 2
observational) with 1182 patients (DES¼634 CABG¼548). Mean age was 62 years
and 79% were males in both groups. Follow up period varied from 6 months to 10
years with a mean follow up of 4730 patient-years. DES types used included
Paclitaxel, Sirolimus and Everolimus eluting stents. All CABG surgeries involved
IMA graft while 78% of the CABG were done off-pump using lateral thoracotomy
approach. There was no difference in all-cause mortality (RR: 1.20 95% CI: 0.51-
2.83, p¼0.67), cardiovascular mortality (RR: 0.43 95% CI: 0.11-1.64, p¼0.21), MI
(RR: 0.56 95% CI: 0.20-1.52, p¼0.25) & stroke (RR: 0.55 95% CI: 0.09-3.44,
p¼0.51) rates between DES and CABG. TVR rate was also similar between two
groups (DES Vs CABG RR: 2.20 95% CI: 0.74-649, p¼0.15). Subgroup analysis of
these outcomes both early (< 30days) and late (>30days) after the procedure did
not show any difference between both treatment strategies. Hospital stay however
was signiﬁcantly lower in the DES group as expected (SMD¼ -9.1 days 95% CI:
14.06-4.14, p< 0.001).
Conclusions: DES in comparison to CABG for revascularization of isolated proximal
LAD stenosis is associated with similar outcomes including the TVR rates while the
hospital stay is signiﬁcantly lower.
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Background: The treatment of patients with multi-vessel (MV) disease for percuta-
neous coronary intervention has increased, especially since the introduction of drug
eluting stents, although MV stenting is associated with increased risk of clinical events
compared to patients with single-vessel (SV) treatment. As the appropriate treatment
of which lesions and vessels to stent continues to be investigated, we sought to
evaluate clinical outcomes of MV (2 vessels) stenting with ResoluteTM zotar-
olimus-eluting stent (R-ZES).
Methods: The RESOLUTE global clinical program enrolled 7618 patients treated
with R-ZES. Target Lesion Failure (TLF) is deﬁned as a composite of death from
cardiac causes, target vessel myocardial infarction (TV-MI), and clinically-indicated
target lesion revascularization (TLR). All clinical results in the extended pooled
analysis are calculated using the Kaplan Meier (KM) method. Given differences in
baseline characteristics, patients were matched by propensity scores based on 26
baseline variables and adjusted p-values are provided.
Results: Among 1562 patients treated by MV and 6056 by SV, MV patients had more
complex baseline characteristics than SV patients. At 3 years, TLR (Figure), TLF
(11.0% vs. 9.2%, p¼0.48), cardiac death or TV-MI (6.9% vs 5.8%, p¼0.29), and
ARC deﬁnite/probable stent thrombosis (1.3% vs. 0.9%, p¼0.91) were similar in MV
and SV patients, respectively.
Conclusions: Across the RESOLUTE global clinical program, R-ZES for MV
treatment provided excellent clinical outcomes, with no increased risk as compared
with SV treatment, through long-term follow-up. Submitted on behalf of the RESO-
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